Tandem Diabetes Care Inc (NASDAQ: TNDM)’s stock price has decreased by -5.15 compared to its previous closing price of 18.64. However, the company has seen a -12.39% decrease in its stock price over the last five trading sessions. zacks.com reported 2025-06-23 that Tandem Diabetes’ t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
Is It Worth Investing in Tandem Diabetes Care Inc (NASDAQ: TNDM) Right Now?
Tandem Diabetes Care Inc (NASDAQ: TNDM) has a price-to-earnings ratio of N/Ax that is above its average ratio. Additionally, the 36-month beta value for TNDM is 1.49. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 11 rating it as “hold,” and 0 rating it as “sell.”
The average price predicted by analysts for TNDM is N/A, which is -$1539964.71 below the current price. The public float for TNDM is 65.97M and currently, short sellers hold a 13.38% ratio of that float. The average trading volume of TNDM on July 01, 2025 was 1.54M shares.
TNDM’s Market Performance
TNDM stock saw a decrease of -12.39% in the past week, with a monthly decline of -10.80% and a quarterly a decrease of -7.72%. The volatility ratio for the week is 5.20%, and the volatility levels for the last 30 days are 5.32% for Tandem Diabetes Care Inc (TNDM). The simple moving average for the last 20 days is -12.27% for TNDM stock, with a simple moving average of -38.35% for the last 200 days.
Analysts’ Opinion of TNDM
Many brokerage firms have already submitted their reports for TNDM stocks, with Truist repeating the rating for TNDM by listing it as a “Hold.” The predicted price for TNDM in the upcoming period, according to Truist is $24 based on the research report published on June 16, 2025 of the current year 2025.
Mizuho, on the other hand, stated in their research note that they expect to see TNDM reach a price target of $20. The rating they have provided for TNDM stocks is “Neutral” according to the report published on April 10th, 2025.
Morgan Stanley gave a rating of “Equal-Weight” to TNDM, setting the target price at $22 in the report published on March 05th of the current year.
TNDM Trading at -13.31% from the 50-Day Moving Average
After a stumble in the market that brought TNDM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.35% of loss for the given period.
Volatility was left at 5.32%, however, over the last 30 days, the volatility rate increased by 5.20%, as shares sank -13.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.56% upper at present.
During the last 5 trading sessions, TNDM fell by -13.48%, which changed the moving average for the period of 200-days by -59.14% in comparison to the 20-day moving average, which settled at $20.14. In addition, Tandem Diabetes Care Inc saw -56.27% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNDM starting from Kyrillos Jean-Claude, who purchase 10,538 shares at the price of $18.12 back on Mar 07 ’25. After this action, Kyrillos Jean-Claude now owns 10,538 shares of Tandem Diabetes Care Inc, valued at $190,966 using the latest closing price.
BLICKENSTAFF KIM D, the Director of Tandem Diabetes Care Inc, sale 30,000 shares at $31.38 during a trade that took place back on Nov 21 ’24, which means that BLICKENSTAFF KIM D is holding 165,190 shares at $941,400 based on the most recent closing price.
Stock Fundamentals for TNDM
Current profitability levels for the company are sitting at:
- -0.16 for the present operating margin
- 0.47 for the gross margin
The net margin for Tandem Diabetes Care Inc stands at -0.17. The total capital return value is set at -0.28. Equity return is now at value -92.31, with -19.74 for asset returns.
Based on Tandem Diabetes Care Inc (TNDM), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.03. The debt to equity ratio resting at 3.18. The interest coverage ratio of the stock is -32.32.
Currently, EBITDA for the company is -99.13 million with net debt to EBITDA at -2.92. When we switch over and look at the enterprise to sales, we see a ratio of 1.48. The receivables turnover for the company is 8.71for trailing twelve months and the total asset turnover is 1.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.30.
Conclusion
In conclusion, Tandem Diabetes Care Inc (TNDM) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
